{"url_path":"/sec/adct/8-k/2026-06-03/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1771910/0000950103-26-008465-index.html","accession_number":"0000950103-26-008465","cik":"0001771910","ticker":"ADCT","issuer_name":"ADC Therapeutics SA","edgar_url":"https://www.sec.gov/Archives/edgar/data/1771910/0000950103-26-008465-index.html","primary_entity_key":"0001771910","primary_entity_name":"ADC Therapeutics SA"},"word_count":133,"has_tables":true,"body_markdown":"**Item 7.01. Regulation FD Disclosure.**\n\n \n\nIn connection with the events described under Item 8.01 below, ADC\nTherapeutics SA (the “Company”) issued a press release and made available a presentation, copies of which are attached as\nExhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and incorporated by reference herein.\n\n \n\nThe information contained in this Item 7.01 and the associated exhibits\nshall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange\nAct”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under\nthe Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing."}